loading
Schlusskurs vom Vortag:
$3.15
Offen:
$3.16
24-Stunden-Volumen:
335.90K
Relative Volume:
0.85
Marktkapitalisierung:
$246.10M
Einnahmen:
$351.37M
Nettoeinkommen (Verlust:
$-174.01M
KGV:
-1.5217
EPS:
-2.07
Netto-Cashflow:
$-126.94M
1W Leistung:
-1.56%
1M Leistung:
+6.42%
6M Leistung:
-0.32%
1J Leistung:
+7.51%
1-Tages-Spanne:
Value
$3.11
$3.1799
1-Wochen-Bereich:
Value
$3.105
$3.23
52-Wochen-Spanne:
Value
$2.455
$4.02

Atea Pharmaceuticals Inc Stock (AVIR) Company Profile

Name
Firmenname
Atea Pharmaceuticals Inc
Name
Telefon
857-204-8109
Name
Adresse
225 FRANKLIN STREET, BOSTON
Name
Mitarbeiter
56
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
AVIR's Discussions on Twitter

Vergleichen Sie AVIR mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
AVIR
Atea Pharmaceuticals Inc
3.15 246.10M 351.37M -174.01M -126.94M -2.07
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
455.71 114.69B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
752.62 77.91B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ARGX
Argen X Se Adr
850.95 54.05B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
391.50 52.52B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
INSM
Insmed Inc
196.92 42.02B 447.02M -1.18B -906.14M -6.1812

Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-08-13 Hochstufung Morgan Stanley Underweight → Equal-Weight
2023-08-10 Herabstufung JP Morgan Neutral → Underweight
2022-01-06 Herabstufung Morgan Stanley Equal-Weight → Underweight
2021-11-18 Herabstufung SVB Leerink Outperform → Mkt Perform
2021-10-20 Herabstufung JP Morgan Overweight → Neutral
2021-10-05 Herabstufung Morgan Stanley Overweight → Equal-Weight
2020-11-25 Eingeleitet Evercore ISI Outperform
2020-11-24 Eingeleitet JP Morgan Overweight
2020-11-24 Eingeleitet Morgan Stanley Overweight
2020-11-24 Eingeleitet William Blair Outperform
Alle ansehen

Atea Pharmaceuticals Inc Aktie (AVIR) Neueste Nachrichten

pulisher
Dec 11, 2025

Atea Pharmaceuticals (NASDAQ:AVIR) Trading Down 1.9%Should You Sell? - MarketBeat

Dec 11, 2025
pulisher
Dec 10, 2025

We're Keeping An Eye On Atea Pharmaceuticals' (NASDAQ:AVIR) Cash Burn Rate - Yahoo Finance

Dec 10, 2025
pulisher
Dec 04, 2025

How Atea Pharmaceuticals Inc. stock trades during market volatilityTrade Risk Assessment & Community Verified Trade Signals - Newser

Dec 04, 2025
pulisher
Dec 03, 2025

Is Atea Pharmaceuticals Inc. stock overvalued by current metricsJuly 2025 Macro Moves & Daily Growth Stock Tips - Newser

Dec 03, 2025
pulisher
Dec 03, 2025

How Atea Pharmaceuticals Inc. stock valuations compare to rivalsTake Profit & Fast Entry High Yield Tips - Newser

Dec 03, 2025
pulisher
Dec 03, 2025

How Atea Pharmaceuticals Inc. stock performs after earningsJuly 2025 Action & AI Enhanced Trading Signals - Newser

Dec 03, 2025
pulisher
Nov 25, 2025

ReAlta Life Sciences Appoints Dr. Howard Berman as Executive Chairman - Stock Titan

Nov 25, 2025
pulisher
Nov 23, 2025

Atea Pharmaceuticals director Franklin Berger acquires $81,498 in stock - MSN

Nov 23, 2025
pulisher
Nov 21, 2025

Will Atea Pharmaceuticals Inc. stock beat EPS estimatesTrade Risk Report & Expert Approved Momentum Trade Ideas - newser.com

Nov 21, 2025
pulisher
Nov 20, 2025

Is Atea Pharmaceuticals Inc. stock reversal real or fake2025 Winners & Losers & Technical Pattern Based Buy Signals - newser.com

Nov 20, 2025
pulisher
Nov 20, 2025

Will Atea Pharmaceuticals Inc. stock outperform growth indexesJuly 2025 Action & Momentum Based Trading Ideas - newser.com

Nov 20, 2025
pulisher
Nov 20, 2025

How strong is Atea Pharmaceuticals Inc. stock revenue growth2025 Historical Comparison & Growth Focused Investment Plans - newser.com

Nov 20, 2025
pulisher
Nov 19, 2025

Atea Pharmaceuticals Inc (AVIR) Q3 2025 Earnings Call Highlights: Strategic Advances in HCV ... By GuruFocus - Investing.com Canada

Nov 19, 2025
pulisher
Nov 19, 2025

Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference - Yahoo Finance

Nov 19, 2025
pulisher
Nov 19, 2025

Is a relief rally coming for Atea Pharmaceuticals Inc. holdersProduct Launch & High Return Trade Opportunity Guides - newser.com

Nov 19, 2025
pulisher
Nov 18, 2025

How Atea Pharmaceuticals Inc. stock performs in rate cut cyclesQuarterly Earnings Summary & Reliable Intraday Trade Alerts - newser.com

Nov 18, 2025
pulisher
Nov 17, 2025

Atea Pharma (AVIR) Earnings Call Transcript - AOL.com

Nov 17, 2025
pulisher
Nov 17, 2025

William Blair Has Negative Outlook of AVIR FY2025 Earnings - Defense World

Nov 17, 2025
pulisher
Nov 16, 2025

Atea Pharmaceuticals Inc. stock trend outlook and recovery pathMarket Growth Report & Reliable Price Action Trade Plans - newser.com

Nov 16, 2025
pulisher
Nov 16, 2025

Live market analysis of Atea Pharmaceuticals Inc.CEO Change & AI Enhanced Market Trend Forecasts - newser.com

Nov 16, 2025
pulisher
Nov 15, 2025

Backtesting results for Atea Pharmaceuticals Inc. trading strategiesJuly 2025 Summary & Real-Time Market Sentiment Reports - newser.com

Nov 15, 2025
pulisher
Nov 15, 2025

Atea Pharmaceuticals’ Earnings Call Highlights Progress and Optimism - MSN

Nov 15, 2025
pulisher
Nov 15, 2025

Key metrics from Atea Pharmaceuticals Inc.’s quarterly dataMarket Trend Report & Fast Moving Stock Trade Plans - newser.com

Nov 15, 2025
pulisher
Nov 14, 2025

What Makes HDFC Mutual fund a Strong Contender in YEAREarnings Call Summaries & Fast Growing Portfolio - earlytimes.in

Nov 14, 2025
pulisher
Nov 14, 2025

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2025 Earnings Call Transcript - Insider Monkey

Nov 14, 2025
pulisher
Nov 14, 2025

Atea Pharmaceuticals, Inc. 2025 Q3ResultsEarnings Call Presentation (NASDAQ:AVIR) 2025-11-14 - Seeking Alpha

Nov 14, 2025
pulisher
Nov 12, 2025

Atea Pharmaceuticals Advances Antiviral Programs with New Data - TipRanks

Nov 12, 2025
pulisher
Nov 12, 2025

Atea Pharmaceuticals Q3 2025 Earnings Call Transcript - MarketBeat

Nov 12, 2025
pulisher
Nov 12, 2025

Earnings call transcript: Atea Pharmaceuticals Q3 2025 sees EPS miss By Investing.com - Investing.com Nigeria

Nov 12, 2025

Finanzdaten der Atea Pharmaceuticals Inc-Aktie (AVIR)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$38.53
price up icon 0.36%
$98.64
price up icon 3.39%
$31.57
price up icon 0.83%
$93.81
price down icon 1.05%
biotechnology ONC
$310.67
price down icon 2.63%
$196.92
price down icon 0.05%
Kapitalisierung:     |  Volumen (24h):